Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy
- PMID: 28577231
- DOI: 10.1007/s00520-017-3764-y
Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy
Abstract
Purpose: The aim of this study is to examine and compare with the validated, paper/pencil European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale (QLQ-CIPN20), the psychometric properties of three electronically administered patient reported outcome (PRO) measures of chemotherapy-induced peripheral neuropathy (CIPN): (1) the two neuropathy items from the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), (2) the QLQ-CIPN20, and (3) the 0-10 Neuropathy Screening Question (NSQ).
Methods: We employed a descriptive, cross-sectional design and recruited 25 women with breast cancer who were receiving neurotoxic chemotherapy at an academic hospital. Participants completed the paper/pencil QLQ-CIPN20 and electronic versions of the QLQ-CIPN20, PRO-CTCAE, and NSQ. Internal consistency reliability, intraclass correlation, and concurrent and discriminant validity analyses were conducted.
Results: The alpha coefficients for the electronic QLQ-CIPN20 sensory and motor subscales were 0.76 and 0.75. Comparison of the electronic and paper/pencil QLQ-CIPN20 subscales supported mode equivalence (intraclass correlation range >0.91). Participants who reported the presence of numbness/tingling via the single-item NSQ reported higher mean QLQ-CIPN20 sensory subscale scores (p < 0.001). PRO-CTCAE neuropathy severity and interference items correlated well with the QLQ-CIPN20 electronic and paper/pencil sensory (r = 0.76; r = 0.70) and motor (r = 0.55; r = 0.62) subscales, and with the NSQ (r = 0.72; r = 0.44).
Conclusion: These data support the validity of the electronically administered PRO-CTCAE neuropathy items, NSQ, and QLQ-CIPN20 for neuropathy screening in clinical practice. The electronic and paper/pencil versions of the QLQ-CIPN can be used interchangeably based on evidence of mode equivalence.
Keywords: Chemotherapy-induced peripheral neuropathy; Patient-reported outcomes; Peripheral nervous system disease/chemically induced; Psychometrics.
Similar articles
-
Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data.Cancer Nurs. 2019 May/Jun;42(3):179-189. doi: 10.1097/NCC.0000000000000596. Cancer Nurs. 2019. PMID: 29649081 Free PMC article.
-
Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).Asia Pac J Clin Oncol. 2019 Feb;15(1):56-62. doi: 10.1111/ajco.13000. Epub 2018 Jun 5. Asia Pac J Clin Oncol. 2019. PMID: 29873180
-
Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.J Patient Rep Outcomes. 2021 Sep 26;5(1):101. doi: 10.1186/s41687-021-00377-z. J Patient Rep Outcomes. 2021. PMID: 34568984 Free PMC article.
-
[Chemotherapy-induced peripheral neuropathy; impact on quality of life].Ned Tijdschr Geneeskd. 2014;158:A7455. Ned Tijdschr Geneeskd. 2014. PMID: 25315326 Review. Dutch.
-
Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.Support Care Cancer. 2018 Apr;26(4):1051-1059. doi: 10.1007/s00520-017-4028-6. Epub 2017 Dec 26. Support Care Cancer. 2018. PMID: 29280005
Cited by
-
Describing the minimally clinically important difference of a chemotherapy-induced peripheral neuropathy patient-reported outcome measure in young adults.Asia Pac J Oncol Nurs. 2025 Jan 19;12:100656. doi: 10.1016/j.apjon.2025.100656. eCollection 2025 Dec. Asia Pac J Oncol Nurs. 2025. PMID: 40007520 Free PMC article.
-
Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program.Cancers (Basel). 2022 Jan 28;14(3):660. doi: 10.3390/cancers14030660. Cancers (Basel). 2022. PMID: 35158928 Free PMC article.
-
Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events.BMC Cancer. 2021 Jul 27;21(1):860. doi: 10.1186/s12885-021-08610-0. BMC Cancer. 2021. PMID: 34315423 Free PMC article.
-
Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data.Cancer Nurs. 2019 May/Jun;42(3):179-189. doi: 10.1097/NCC.0000000000000596. Cancer Nurs. 2019. PMID: 29649081 Free PMC article.
-
Remote Monitoring of Chemotherapy-Induced Peripheral Neuropathy by the NeuroDetect iOS App: Observational Cohort Study of Patients With Cancer.J Med Internet Res. 2025 Feb 5;27:e65615. doi: 10.2196/65615. J Med Internet Res. 2025. PMID: 39908091 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical